[i] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206.

[ii] Stankiewicz J, Tami T, Truitt T, Atkins J, Liepert D, Winger B. Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia. Am J of Rhinology. 2009 May-June; 321-327.

[iii] Gould, J. In-office balloon dilation: Procedure techniques and outcomes using a malleable multi-sinus dilation tool. ENT Journal. Vendome Healthcare Media, 19 Dec 2012.

[iv] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206

The benefits of office sinus dilation include:

  • Delivers instant, lasting relief. [i],[ii]
  • Convenient, comfortable office procedure. [iii]
  • Quick recovery—most patients return to normal activity in 24 hours. [iv]
  • May reduce healthcare costs

XprESS

Instant Relief That Lasts

 

Office sinus dilation is a minimally invasive option that can be performed by Dr. Neal right here, in our offices. The goal of office sinus dilation is to reshape anatomy to expand sinus pathways and restore drainage.

 

The procedure utilizes small balloons placed in key places in the nose and sinus, which are then dilated to expand the sinus pathways. It may be an effective, lasting option for some patients whose symptoms do not resolve with medication.

[1] SINUVA Prescribing Information, Intersect ENT. December 2017
[2] Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol.2018;8:471–81.

Sinusitis Treatment: Office Sinus Dilation now offered at Harrisonburg ENT Assoc.

SINUVA was clinically proven to    [1],[2]

  1. Shrink nasal polyps at 90 days
  2. Reduce symptoms of nasal obstruction and congestion
  3. Improve patients altered sense of smell

Chronic Sinusitis Patients Have A New Weapon - PROPEL

The most common adverse reactions observed in clinical trials were bronchitis, upper respiratory or middle ear infection, headache, light-headedness, asthma and nose bleed.  SINUVA is not for people with hypersensitivity to corticosteroids or those with nasal ulcers or trauma. Important Safety Information can be found at https://www.sinuva.com/safety.

Pilot study results: Murr AH, Smith TL, Hwang PH, et al. IFAR. 2011;1:23–32.; ADVANCE II clinical trial: Marple BF, Smith TL, Han JK et al. Otolaryngol Head Neck Surg.2012; 146(6) 1004-1011.; Meta-analysis: Han JK, Marple BF, Smith TL et al IFAR. 2012; 2 :271-279.
​Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000;110:29–31.

Harrisonburg ENT Associates

PROPEL

Choosing SINUVA Sinus Implants

SINUVA may be appealing to nasal polyp sufferers who would prefer an in-office treatment instead of sinus surgery in an operating room. SINUVA is placed during an office visit and patients are usually able to resume normal activities with little to no recovery days needed.

Discuss sinus treatment options with
Dr. Neal & Dr. Johnson today!
 
Dr. Neal & Dr. Johnson are trained and experienced users of office sinus dilation technologies and steroid-releasing implants. Make an appointment at Harrisonburg ENT Assoc. today to determine what the best treatment is for you.
The goal of surgical treatment for chronic sinusitis is to enlarge the inflamed or obstructed sinus passageways.  Post-surgery check-ups are required to inspect the sinus cavities to monitor for inflammation and scarring and treat accordingly with surgery and/or oral steroids.

The dissolveable PROPEL Steroid-Releasing Implant is the first in a new category of products offering localized, controlled delivery of steroid directly to the sinus tissue to maintain the openings created in surgery.


Applying principles of coronary drug-eluting stents to sinusitis sufferers, the spring-link implants gradually deliver an advanced steroid with anti-inflammatory properties (mometasone furoate) directly to the sinus lining, then dissolve into the body following endoscopic sinus surgery.  The result is improved surgical outcomes, reducing the need for additional surgical procedures and for systematic steroids, which can have serious side effects.


Three rigorous clinical trials4 have demonstrated that the implant is safe and maintains the results of sinus surgery by propping open the sinus cavities and decreasing post-operative scarring and inflammation.  Reducing these factors is proven to improve long-term outcomes5 and to reduce the need for repeat surgery and oral steroids, which can have serious side effects.  PROPEL is the only product used in sinus surgery to be supported by level 1-A evidence.